Remedy for spinal injury containing interleukin-6 antagonist

• US 20060165696A1
• Filed: 02/24/2004
• Published: 07/27/2006
• Est. Priority Date: 02/24/2003
• Status: Abandoned Application

• Current Assignee: KEIO University, Chugai Seiyaku Kabushiki Kaisha (Roche Holding AG)
• Original Assignee: Chugai Seiyaku Kabushiki Kaisha KEIO University
• Inventors: Yoshizaki, Kazuyuki, Okada, Seiji, Okano, Hideyuki, Nakamura, Masaya
• Application Number:
  US10/546,149
• Publication Number:
  US 20060165696A1
• Time in Patent Office: Days
• US Class Current: 424/145.100
• CPC Class Codes: A61K 2039/505 comprising antibodies
• CPC Class Codes: A61K 38/00 Medicinal preparations containing peptides peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00
• CPC Class Codes: A61P 19/00 Drugs for skeletal disorders
• CPC Class Codes: A61P 25/00 Drugs for disorders of the nervous system
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: C07K 16/248 IL-6
• CPC Class Codes: C07K 16/2866 against receptors for cytokines, lymphokines, interferons

Abstract

A therapeutic agent for spinal cord injury, a modulator of differentiation of neural stem cells and an inhibitor of differentiation into glia cells comprising an interleukin-6 antagonist as an active ingredient.

Claims

1. A therapeutic agent for spinal cord injury comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

2. The therapeutic agent for spinal cord injury according to claim 1 wherein said IL-6 antagonist is an antibody against IL-6 receptor.

3. The therapeutic agent for spinal cord injury according to claim 2 wherein said antibody is a monoclonal antibody.

4. The therapeutic agent for spinal cord injury according to claim 2 wherein said antibody is a monoclonal antibody against human IL-6 receptor.

5. The therapeutic agent for spinal cord injury according to claim 2 wherein said antibody is a monoclonal antibody against mouse IL-6 receptor.

6. The therapeutic agent for spinal cord injury according to claim 1 wherein said antibody is a recombinant antibody.

7. The therapeutic agent for spinal cord injury according to claim 1 wherein said monoclonal antibody against human IL-6 receptor is PM-1 antibody.

8. The therapeutic agent for spinal cord injury according to claim 5 wherein said monoclonal antibody against mouse IL-6 receptor is MR16-1 antibody.

9. The therapeutic agent for spinal cord injury according to claim 1 wherein said antibody is a chimeric antibody, a humanized antibody, or a human antibody against IL-6 receptor.

10. The therapeutic agent for spinal cord injury according to claim 9 wherein said humanized antibody is a humanized PM-1 antibody.

11. A modulator of differentiation of neural stem cells comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

12. An inhibitor of differentiation into glia cells comprising an interleukin-6 (IL-6) antagonist as an active ingredient.

13-24. -24. (canceled)

25. A therapeutic method for spinal cord injury of a subject which comprises administering an interleukin-6 (IL-6) antagonist to the subject.

26. The method according to claim 25 wherein said IL-6 antagonist is an antibody against IL-6 receptor.

27. The method according to claim 26 wherein said antibody is a monoclonal antibody.

28. The method according to claim 26 wherein said antibody is a monoclonal antibody against human IL-6 receptor.

29. The method according to claim 26 wherein said antibody is a monoclonal antibody against mouse IL-6 receptor.

30. The method according to claim 25 wherein said antibody is a recombinant antibody.

31. The method according to claim 25 wherein said monoclonal antibody against human IL-6 receptor is PM-1 antibody.

32. The method according to claim 29 wherein said monoclonal antibody against mouse IL-6 receptor is MR 16-1 antibody.

33. The method according to claim 25 wherein said antibody is a chimeric antibody, a humanized antibody, or a human antibody against IL-6 receptor.

34. The method according to claim 33 wherein said humanized antibody is a humanized PM-1 antibody.

35. A method of modulating the differentiation of neural stem cells of a subject which comprises administering an interleukin-6 (IL-6) antagonist to the subject.

36. A method of inhibiting differentiation into glia cells, in a subject, which comprises administering an interleukin-6 (IL-6) antagonist to the subject.